Magnesium Sulfuricum Bbp (Magnesium Sulfate Heptahydrate)

Magnesium sulfate releases magnesium ions that serve as essential cofactors for many enzymatic processes, stabilize cell membranes, and modulate calcium channels. This action helps reduce neuronal excitability, supports normal muscle and nerve function, and stabilises cardiac electrical activity.

The specific dose and administration schedule are determined by the prescribing clinician based on the patient’s condition, serum magnesium level, renal function, and route of administration. Healthcare professionals tailor the regimen to achieve therapeutic magnesium concentrations safely.

Magnesium sulfate is commonly used in obstetric care for eclampsia and pre‑eclampsia, but safety depends on clinical judgment. The product should only be used during pregnancy or lactation when the prescriber deems the benefits outweigh any potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Magnesium Sulfuricum Bbp provides magnesium sulfate in an injectable form, allowing rapid correction of serum magnesium levels, which is advantageous over oral magnesium salts when immediate effect is required, such as in acute eclampsia or severe arrhythmias. Oral preparations act more slowly and may have gastrointestinal side effects.

The product should be stored at 2‑8 °C, kept in its original packaging, protected from light, and must not be frozen or shaken. Proper refrigeration maintains stability and potency of the injectable solution.

Magnesium Sulfuricum Bbp is administered by a healthcare professional via intramuscular, intravenous, or subcutaneous injection, depending on the clinical situation. The route, rate, and total dose are selected by the prescriber to achieve the desired therapeutic effect while monitoring the patient.

Serious risks include severe hypotension, hypermagnesemia leading to respiratory depression, cardiac arrest, and rare allergic reactions such as anaphylaxis. Continuous monitoring of vital signs and serum magnesium levels helps mitigate these risks.

Patients with known hypersensitivity to magnesium sulfate, existing hypermagnesemia, severe renal impairment without dose adjustment, or uncontrolled cardiac conduction disorders should not receive this product unless a prescriber determines that benefits outweigh the risks.